journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/28635362/costs-and-effectiveness-of-fingolimod-versus-alemtuzumab-in-the-treatment-of-highly-active-relapsing-remitting-multiple-sclerosis-in-the-uk-retreatment-discount-and-disutility
#1
Stephen M Montgomery, Jeanette Kusel, Richard Nicholas, Nicholas Adlard
OBJECTIVE: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with disease modifying therapies (DMTs) who continue to experience disease activity may be considered for escalation therapies such as fingolimod or may be considered for alemtuzumab. Previous economic modelling used Markov models; applying one alternative technique, discrete event simulation (DES) modelling, allows retreatment and long-term adverse events (AEs) to be included in the analysis. METHODS: A DES was adapted to model relapse-triggered retreatment with alemtuzumab and the effect of including ongoing quality-adjusted life year (QALY) decrements for AEs that extend beyond previous one year Markov cycles...
June 21, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28635342/healthcare-costs-in-psoriasis-and-psoriasis-subgroups-over-time-following-psoriasis-diagnosis
#2
Sarah Al Sawah, Shonda A Foster, Orin M Goldblum, William N Malatestinic, Baojin Zhu, Nianwen Shi, Xue Song, Steven R Feldman
AIMS: To quantify healthcare costs in patients with psoriasis overall and, in psoriasis patient subgroups, by level of disease severity, presence or absence of psoriatic arthritis, or use of biologics. METHODS: Administrative data from Truven Health Analytics MarketScan Research Database were used to select adult patients with psoriasis from January 2009 to January 2014. The first psoriasis diagnosis was set as the index date. Patients were required to have ≥6 months of continuous enrollment with medical and pharmacy benefits pre-index and ≥12 months post-index...
June 21, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28635339/methods-for-estimating-costs-in-patients-with-hyperlipidemia-experiencing-their-first-cardiovascular-event-in-the-united-kingdom
#3
Mark D Danese, Michelle Gleeson, Robert I Griffiths, David Catterick, Lucie Kutikova
AIMS: Methods for integrating external costs into clinical databases are not well-characterized. The purpose of this research was to describe and implement methods for estimating the cost of hospitalizations, prescriptions, and general practitioner and specialist visits used to manage hyperlipidemia patients experiencing cardiovascular (CV) events in the United Kingdom (UK). METHODS: This study was a retrospective cohort study using the Clinical Practice Research Datalink and Hospital Episode Statistics data...
June 21, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28631497/cost-effectiveness-of-blinatumomab-versus-salvage-chemotherapy-in-relapsed-or-refractory-philadelphia-chromosome-negative-b-precursor-acute-lymphoblastic-leukemia-from-a-us-payer-perspective
#4
Thomas E Delea, Jordan Amdahl, Diana Boyko, May Hagiwara, Zachary F Zimmerman, Janet L Franklin, Ze Cong, Guy Hechmati, Anthony Stein
Objective To evaluate the cost-effectiveness of blinatumomab (Blincyto) versus standard of care (SOC) chemotherapy in adults with relapsed or refractory (R/R) Philadelphia-chromosome-negative (Ph-) B-precursor acute lymphoblastic leukemia (ALL) based on the results of the phase 3 TOWER study from a US healthcare payer perspective. Methods The Blincyto Global Economic Model (B-GEM), a partitioned survival model, was used to estimate the incremental cost-effectiveness ratio (ICER) of blinatumomab versus SOC. Response rates, event free survival (EFS), overall survival (OS), numbers of cycles of blinatumomab and SOC, and transplant rates were estimated from TOWER...
June 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28581873/budget-impact-model-in-moderate-to-severe-psoriasis-vulgaris-assessing-effects-of-calcipotriene-and-betamethasone-dipropionate-foam-on-per-patient-standard-of-care-costs
#5
Carl V Asche, Minchul Kim, Steven R Feldman, Panagiotis Zografos, Minyi Lu
AIMS: To develop a budget impact model (BIM) for estimating the financial impact of formulary adoption and uptake of calcipotriene and betamethasone dipropionate (C/BD) foam (0.005%/0.064%) on the costs of biologics for treating moderate-to-severe psoriasis vulgaris in a hypothetical US healthcare plan with 1 million members. METHODS: This BIM incorporated epidemiologic data, market uptake assumptions, and drug utilization costs, simulating the treatment mix for patients who are candidates for biologics before (Scenario #1) and after (Scenario #2) the introduction of C/BD foam...
June 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28562140/the-effects-of-global-budget-on-cost-control-and-readmission-in-rural-china-a-difference-in-difference-analysis
#6
Ruibo He, Yudong Miao, Ting Ye, Yan Zhang, Wenxi Tang, Zhong Li, Liang Zhang
BACKGROUND: Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural China. METHODS: YC county was chosen as the intervention group, with 33,175 inpatients before and 36,883 inpatients after the reform (2012 and 2014, respectively)...
June 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28562131/cost-reduction-from-resolution-improvement-of-carcinoid-syndrome-symptoms-following-treatment-with-above-standard-dose-of-octreotide-lar
#7
Lynn Huynh, Todor Totev, Francis Vekeman, Maureen P Neary, Mei S Duh, Al B Benson
AIMS: To calculate the cost reduction associated with diarrhea/flushing symptom resolution/improvement following treatment with above-standard dose octreotide-LAR from the commercial payor's perspective. MATERIALS AND METHODS: Diarrhea and flushing are two major carcinoid syndrome symptoms of neuroendocrine tumor (NET). Previously, a study of NET patients from three US tertiary oncology centers (NET 3-Center Study) demonstrated that dose escalation of octreotide LAR to above-standard dose resolved/improved diarrhea/flushing in 79% of the patients within 1 year...
June 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28562132/burden-of-illness-associated-with-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-patients-with-hematopoietic-stem-cell-transplantation
#8
Zhun Cao, Kathleen F Villa, Craig B Lipkin, Scott B Robinson, Bijan Nejadnik, Christopher C Dvorak
AIMS: Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT) associated with significant morbidity and mortality. Healthcare utilization, costs, and mortality were assessed in HSCT patients diagnosed with SOS, with and without multi-organ dysfunction (MOD). MATERIALS AND METHODS: This retrospective observational study identified real-world patients undergoing HSCT between January 1, 2009 and May 31, 2014 using the Premier Healthcare Database...
June 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28562125/a-discrete-choice-experiment-to-determine-uk-patient-preference-for-attributes-of-disease-modifying-treatments-in-multiple-sclerosis
#9
Catherine Bottomley, Andrew Lloyd, Gary Bennett, Nicholas Adlard
AIMS: The recent licensing of Disease Modifying Treatments (DMTs) for Multiple Sclerosis (MS) has increased available treatment options. The aim of this study was to explore MS patients' preference for the different attributes of DMTs in the UK. MATERIALS AND METHODS: Attributes (treatment characteristics) for inclusion in the discrete choice experiment (DCE) were determined through published literature and interviews with 12 people with MS. Seven attributes were selected...
June 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28532191/cost-effectiveness-of-omalizumab-add-on-to-standard-of-care-therapy-in-patients-with-uncontrolled-severe-allergic-asthma-in-a-brazilian-healthcare-setting
#10
Cibele Suzuki, Nilceia Lopes da Silva, Praveen Kumar, Purnima Pathak, Siew Hwa Ong
OBJECTIVE: Omalizumab add-on to standard-of-care therapy has proven to be efficacious in severe asthma patients for whom exacerbations cannot be controlled otherwise. Moreover, evidence from different healthcare settings suggests reduced healthcare resource utilization with omalizumab. Based on these findings, this study aimed to assess the cost-effectiveness of the addition of omalizumab to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting...
June 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28602101/expert-panel-on-practice-patterns-in-the-management-of-cow-s-milk-protein-allergy-and-associated-economic-burden-of-disease-on-health-service-in-turkey
#11
Bulent Enis Sekerel, Oznur Seyhun
AIMS: To evaluate practice patterns in the management of cow's milk protein allergy (CMPA) and associated economic burden of disease on health service in Turkey. MATERIALS AND METHODS: This study was based on experts' views on the practice patterns in management of CMPA manifesting with either proctocolitis or eczema symptoms and, thereby, aimed to estimate economic burden of CMPA. Practice patterns were determined via patient flow charts developed by experts using the modified Delphi method for CMPA presented with proctocolitis and eczema...
June 22, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28604141/cost-effectiveness-of-subdermal-implantable-buprenorphine-versus-sublingual-buprenorphine-to-treat-opioid-use-disorder
#12
John A Carter, Ryan Dammerman, Michael Frost
AIMS: Subdermal implantable buprenorphine (BSI) was recently approved to treat opioid use disorder (OUD) in clinically-stable adults. In the pivotal clinical trial, BSI was associated with a higher proportion of completely-abstinent patients (85.7% vs 71.9%; P = 0.03) versus sublingual buprenorphine (SL-BPN). Elsewhere, relapse to illicit drug use is associated with diminished treatment outcomes and increased costs. Herein, we evaluated the cost-effectiveness of BSI versus SL-BPN from a US societal perspective...
June 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28604139/major-bleeding-risk-and-healthcare-economic-outcomes-of-nonvalvular-atrial-fibrillation-patients-newly-initiated-with-oral-anticoagulant-therapy-in-the-real-world-setting
#13
Jay Lin, Jeffrey Trocio, Kiran Gupta, Jack Mardekian, Melissa Lingohr-Smith, Brandy Menges, Min You, Anagha Nadkarni
AIMS: This study compared the risk for major bleeding (MB) and healthcare economic outcomes of patients with nonvalvular atrial fibrillation (NVAF) after initiating treatment with apixaban versus rivaroxaban, dabigatran, or warfarin. METHODS: NVAF patients who initiated apixaban, rivaroxaban, dabigatran, or warfarin were identified from the IMS Pharmetrics Plus database (1/1/2013-9/30/2015). Propensity score matching (PSM) was used to balance differences in patient characteristics between study cohorts: patients treated with apixaban versus rivaroxaban, apixaban versus dabigatran, and apixaban versus warfarin...
June 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28532187/current-and-projected-patient-and-insurer-costs-for-the-care-of-patients-with-non-small-cell-lung-cancer-in-the-united-states-through-2040
#14
Lisa M Hess, Zhanglin Lin Cui, Yixun Wu, Yun Fang, Paula J Gaynor, Ana B Oton
AIMS: The objective of this study was to quantify the current and to project future patient and insurer costs for the care of patients with non-small cell lung cancer in the US. MATERIALS AND METHODS: An analysis of administrative claims data among patients diagnosed with non-small cell lung cancer from 2007-2015 was conducted. Future costs were projected through 2040 based on these data using autoregressive models. RESULTS: Analysis of claims data found the average total cost of care during first- and second-line therapy was $1,161...
June 9, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28534659/healthcare-costs-among-men-with-favorable-risk-prostate-cancer-managed-with-observation-strategies-versus-immediate-treatment-in-an-integrated-healthcare-system
#15
Furaha Kariburyo, Yuexi Wang, I-Ning Elaine Cheng, Lisa Wang, David Morgenstern, Igor Asner, Lin Xie, Eric Meadows, John Danella
OBJECTIVE: This study explored short-term healthcare costs of men managed with observation strategies (OBS) vs immediate treatment (IMT) for favorable risk prostate cancer (PCa) from the Geisinger Health System, a single integrated health system in Pennsylvania, as evidence from the community setting is limited. METHODS: A retrospective cohort study was conducted using electronic health records from men aged ≥40 years diagnosed with favorable risk PCa (T1 or 2, PSA ≤15 ng/mL, Gleason ≤7 [3 + 4]) between January 2005 and October 2013...
June 8, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28532194/cost-effectiveness-of-ceftolozane-tazobactam-plus-metronidazole-compared-with-piperacillin-tazobactam-as-empiric-therapy-for-the-treatment-of-complicated-intra-abdominal-infections-based-on-the-in-vitro-surveillance-of-bacterial-isolates-in-the-uk
#16
Vimalanand Prabhu, Jason Foo, Harblas Ahir, Eric Sarpong, Sanjay Merchant
AIMS: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently. A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in UK hospitals...
June 8, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28532192/pharmaceutical-expenditure-dynamics-in-the-balkan-countries
#17
Ana V Pejcic, Mihajlo Jakovljevic
No abstract text is available yet for this article.
June 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28485692/cost-effectiveness-of-denosumab-versus-zoledronic-acid-for-preventing-skeletal-related-events-in-the-czech-republic
#18
Joaquim Cristino, Jíndřich Finek, Petra Jandova, Martin Kolek, Bálint Pásztor, Christina Giannopoulou, Yi Qian, Tomas Brezina, Mickael Lothgren
AIMS: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic. MATERIALS AND METHODS: A lifetime Markov model was developed to compare the effects of denosumab and zoledronic acid on costs (including drug costs and administration, patient management, SREs, and adverse events), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from a national payer perspective...
June 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28581874/cost-drivers-for-breast-lung-and-colorectal-cancer-care-in-a-commercially-insured-population-over-a-six-month-episode-an-economic-analysis-from-the-payer-perspective
#19
Bhuvana Sagar, Yu Shen Lin, Liana D Castel
AIMS: In the absence of clinical data, accurate identification of cost drivers is needed for economic comparison in an alternate payment model. From a payer perspective using claims data in a commercial population, our objective was to identify and quantify the effects of cost drivers in economic models of breast, lung, and colorectal cancer costs over a six-month episode following initial chemotherapy. RESEARCH DESIGN AND METHODS: We analyzed claims data from 9,748 Cigna beneficiaries with diagnosis of breast, lung, and colorectal cancer following initial chemotherapy from January 1, 2014 to December 31, 2015...
June 5, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28521540/cost-effectiveness-analysis-of-rivaroxaban-for-treatment-and-secondary-prevention-of-venous-thromboembolism-in-the-netherlands
#20
Marieke Heisen, Maarten J Treur, Harald E Heemstra, Eric B W Giesen, Maarten J Postma
BACKGROUND: Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a novel oral anticoagulant associated with a significantly lower risk of major bleeds (hazard ratio 0.54, 95% confidence interval 0.37-0.79) compared to LMWH/VKA therapy and does not require regular anticoagulation monitoring...
May 18, 2017: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"